Search This Blog

Wednesday, November 30, 2022

First Wave files IND for cystic fibrosis, pancreas med

 Upon IND clearance, Phase 2 clinical trial investigating adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis is expected to initiate in early 2023 with topline clinical data anticipated in the first half of 2023

https://finance.yahoo.com/news/first-wave-biopharma-files-investigational-120000369.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.